Why the study?
Does Angiotensin II induce IRS-1 degradation and impair insulin signaling in vascular smooth muscle cells?
Does Angiotensin II induce IRS-1 degradation and impair insulin signaling in vascular smooth muscle cells?
Angiotensin II impairs insulin signaling in vascular smooth muscle cells by promoting ROS-dependent IRS-1 degradation, providing a molecular mechanism for the beneficial metabolic effects of angiotensin receptor blockers.
Answers are grounded in this paper and cite their sources.
May explain Ang II effects on vascular insulin signaling in animals; leaves open translation to ARB metabolic benefits in humans.
OBJECTIVE: Angiotensin II has been implicated in the pathogenesis of the vascular complications of insulin resistance. Recently, serine phosphorylation and degradation of insulin receptor substrate-1 (IRS-1) were shown to inhibit Akt activation and reduce glucose uptake. Therefore, we examined the effects of chronic angiotensin II treatment on IRS-1 phosphorylation and protein expression in vascular smooth muscle cells (VSMCs). METHODS AND RESULTS: Using Western analysis, we found that angiotensin II (100 nmol/L; 18 hours) caused a 61+/-5% degradation of IRS-1 and abolished insulin-induced activation of Akt. Phosphorylation of IRS-1 on Ser307, which leads to subsequent IRS-1 degradation, was stimulated by angiotensin II. This phosphorylation was blocked by the Src inhibitor PP1 and by the antioxidants N-acetylcysteine and ebselen. Stable overexpression of catalase abrogated angiotensin II-induced IRS-1 phosphorylation and IRS-1 degradation. Similarly, a mutant phosphoinositide-dependent kinase-1 (PDK1) that cannot associate with Src abolished IRS-1 phosphorylation and degradation induced by angiotensin II. Proteasome inhibitors also prevented IRS-1 degradation. CONCLUSIONS: Thus, angiotensin II decreases IRS-1 protein levels in VSMCs via Src, PDK1, and reactive oxygen species-mediated phosphorylation of IRS-1 on Ser307 and subsequent proteasome-dependent degradation. These events impair insulin signaling and provide a molecular basis for understanding the clinical observation that angiotensin II type 1 receptor antagonists improve insulin resistance and its associated vasculopathies.
No takes yet. Share an insight, caveat, or question.
Taniyama et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: